ALA is available in the form of oral supplementation and intravenous injection. Studies postulate promising therapeutic properties in several conditions, including type 1 and 2 diabetes mellitus (DM), neuropathy, and ischemic-perfusion injury.

**Oral:**Data demonstrates daily oral supplementation of 300 mg of ALA over the course of 3 months maintains and improves functional vision in type 1 and type 2 diabetes mellitus patients, respectively.

**Intravenous injection:**The study shows evidence for IV treatment of daily 600 mg in improving positive neuropathic symptoms and neuropathic deficits.